anti-CD3/anti-HER2 bispecific T-cell engager (Beijing Hanmi Pharmaceutical)

N/A

Report date: 2026/03/19 16:53:46

Base Information

Drug Nameanti-CD3/anti-HER2 bispecific T-cell engager (Beijing Hanmi Pharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsReceptor protein-tyrosine kinase erbB-2 modulators
TargetsT cell surface glycoprotein CD3Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Hanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Hanmi Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A